Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 72 (1), 45-48

The Oral Progestational and Anti-Ovulatory Properties of Megestrol Acetate and Its Therapeutic Use in Gynaecological Disorders

  • PMID: 12332461

The Oral Progestational and Anti-Ovulatory Properties of Megestrol Acetate and Its Therapeutic Use in Gynaecological Disorders

E Ostergaard. J Obstet Gynaecol Br Emp.

Abstract

PIP: Megestrol acetate alone (47 cases), combined (115 cases) with mestranol, or sequential with dienestrol diacetate, was prescribed for various gynecologic disorders or for studies of its progestational effects. Doses were usually 1 Planovin tablet (5 mg megestrol acetate and .1 mg mestranol) for 20 day cycles, or from 2.5-15 mg megestrol acetate with or without 2.5-5 mg dienestrol diacetate. Results of treatment were 4 of 10 permanent cures of secondary amenorrhea; 10 permanent cures of dysmenorrhea with temporary improvement in 6; 6 of 7 patients with endometriosis were relieved, although 2 had to maintain cyclic treatment after up to 9 months continuous ingestion; 20 of 21 cases of metrorrhagia were relieved; 6 of 7 women with menopausal symptoms were improved; 18 of 21 women used Planovin successfully for contraception. Studies with 21 women who took megestrol acetate before undergoing planned sterilization showed that neither 5 mg megestrol acetate or .1 mg mestranol alone inhibited ovulation in all women, as observed during laparotomy, but the combined tables was 100% effective.

Similar articles

See all similar articles

Cited by 1 PubMed Central articles

LinkOut - more resources

Feedback